Subscribe to RSS
DOI: 10.1055/s-0042-113468
The Relationship between Psychotropic Drug Use and Suicidal Behavior in Japan: Japanese Adverse Drug Event Report
Publication History
received 18 April 2016
revised 14 July 2016
accepted 19 July 2016
Publication Date:
05 September 2016 (online)
Abstract
Introduction: Very few studies have explored the adverse effect of psychotropic drugs worldwide.
Methods: This study analyzed 1 813 suicide-related drug reports involving 553 patients collected from the Japanese National Adverse Drug Report Database between October 2001 and January 2012 to investigate psychotropic drugs associated with completed suicide vs. other suicide-related behaviors, including ideation and self-injury. The drugs investigated included antidepressants, antipsychotics, benzodiazepines, non-benzodiazepine hypnotic agents, noradrenergic and specific serotonergic antidepressants, selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, and other drugs.
Results: These reports referenced 300 (54.2%) individuals who completed suicide. Adjusting for age, sex, and drugs used, the multivariate model revealed that participants who took antipsychotics were 1.70 times (95% CI, 1.11–2.61) more likely to complete suicide compared with those who did not. All other drugs became non-significant. Compared with those who took only one medication, those prescribed more than 4 drugs were more likely to complete suicide (OR 4.44, 95% CI, 2.40–8.20).
Discussion: Antipsychotic drugs and polypharmacy may be regarded as predictors of completed suicide.
-
References
- 1 Rothman KJ. Causes. Am J Epidemiol 1976; 104: 587-592
- 2 Schaefer M, Capuron L, Friebe A et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol 2012; 57: 1379-1390
- 3 Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat 2011; 18: 153-160
- 4 Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry 2012; 169: 491-497
- 5 Brown ES. Effects of glucocorticoids on mood, memory, and the hippocampus. Treatment and preventive therapy. Ann N Y Acad Sci 2009; 1179: 41-55
- 6 Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73: 207-215
- 7 Yerevanian BI, Choi YM. Impact of psychotropic drugs on suicide and suicidal behaviors. Bipolar Disord 2013; 15: 594-621
- 8 Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-210
- 9 Beasley Jr CM, Dornseif BE, Bosomworth JC et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303: 685-692
- 10 Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332-339
- 11 Stubner S, Grohmann R, von Stralendorff I et al. Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin Psychiatry 2010; 71: 1293-1307
- 12 World Health Organization . Suicide rates per 100 000 by country, year and sex. World Health Organization; 2013. [cited Mar 31 2016]. Available from http://www.who.int/mental_health/prevention/suicide_rates/en/
- 13 Nakao M, Takeuchi T. The suicide epidemic in Japan and strategies of depression screening for its prevention. Bull World Health Organ 2006; 84: 492-493
- 14 National Police Agency web . 2011 National Police Agency. Japan’s suicide statistics in 2010. [cited Mar 31 2016]. Available from http://www.npa.go.jp/safetylife/seianki/H22jisatsunogaiyou.pdf
- 15 Center for suicide prevention web . 2013 Center for suicide prevention. Regional statistics of suicide prevention in Japan (2). [cited Mar 31 2016]. Available from http://ikiru.ncnp.go.jp/ikiru-hp/genjo/toukei/index2.html
- 16 Japanese Cabinet Office Web . 2011 Japanese Cabinet Office, Government of Japan. Suicide prevention. [cited Mar 31 2016]. Available from http://www8.cao.go.jp/jisatsutaisaku/whitepaper/w-2011/html/honpen/part1/s1_1_10.html
- 17 Mann JJ, Apter A, Bertolote J et al. Suicide prevention strategies: a systematic review. JAMA 2005; 294: 2064-2074
- 18 PMDA web . 2012 Pharmaceuticals and Drug Devices Agency. PMDA Updates. ; [cited Mar 31 2016]. Available from http://www.pmda.go.jp/
- 19 PMDA web . 2013 Pharmaceuticals and Drug Devices Agency. Our philosophy. ; [cited Mar 31 2016]. Available from http://www.pmda.go.jp/english/about/philosophy.html
- 20 Tournier M, Grolleau A, Cougnard A et al. The prognostic impact of psychotropic drugs in intentional drug overdose. Pharmacopsychiatry 2009; 42: 51-56
- 21 Ministry of Health Labour and Welfare, Survey of Physicians Dentists and Pharmacists . Measures against overdose. 2010 [cited Mar 31 2016]. Available from http://www.mhlw.go.jp/bunya/shougaihoken/jisatsu/dl/torimatome_5.pdf
- 22 Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-235
- 23 Maust DT, Kim HM, Seyfried LS et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015; 72: 438-445
- 24 Suominen K, Isometsa E, Suokas J et al. Completed suicide after a suicide attempt: a 37-year follow-up study. Am J Psychiatry 2004; 161: 562-563
- 25 Payne RA, Abel GA, Avery AJ et al. Is polypharmacy always hazardous? A retrospective cohort analysis using linked electronic health records from primary and secondary care. Br J Clin Pharmacol 2014; 77: 1073-1082
- 26 Joukamaa M, Heliovaara M, Knekt P et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006; 188: 122-127
- 27 Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325-329
- 28 Galling B, Roldan A, Rietschel L et al. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin Drug Saf 2016; 11: 11
- 29 Cabinet Office . Government of Japan. 2011 [cited Mar 31 2016]. Available from http://www8.cao.go.jp/jisatsutaisaku/whitepaper/w-2011/html/index.html